The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study

被引：0
|
作者：
Tepper, S. [1 ]
Wilson, M. -C. [2 ]
Orejudos, A. [3 ]
Adams, A. Manack [3 ]
Blumenfeld, A. [4 ]
机构：
[1] Geisel Sch Med Dartmouth, Hanover, NH USA
[2] Ochsner Hlth Syst, Covington, LA USA
[3] Allergan Plc, Irvine, CA USA
[4] Headache Ctr Southern Calif, Neurol Cente, Carlsbad, CA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O404
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF ONABOTULINUMTOXINA IN AN OPEN-LABEL STUDY FOR THE PROPHYLACTIC TREATMENT OF CHRONIC MIGRAINE IN ADULT PATIENTS: COMPEL
    Blumenfeld, A.
    Stark, R.
    Adams, A. Manack
    Orejudos, A.
    Aurora, S.
    CEPHALALGIA, 2016, 36 : 27 - 28
  • [32] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [33] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [34] LONG-TERM SAFETY AND TOLERABILITY OF ONABOTULINUMTOXINA TREATMENT IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: COMPEL ANALYSIS BY TREATMENT CYCLE
    Winner, P. K.
    Blumenfeld, A. M.
    Eross, E. J.
    Orejudos, A.
    Adams, A. Manack
    Brin, M. F.
    CEPHALALGIA, 2018, 38 : 75 - 76
  • [35] Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
    Andrew M. Blumenfeld
    Sheena K. Aurora
    Karen Laranjo
    Spyros Papapetropoulos
    BMC Neurology, 15
  • [36] Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
    Blumenfeld, Andrew M.
    Aurora, Sheena K.
    Laranjo, Karen
    Papapetropoulos, Spyros
    BMC NEUROLOGY, 2015, 15
  • [37] OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
    Dressler, Dirk
    BRAIN, 2020, 143
  • [38] Descriptive comparison of the efficacy and safety of onabotulinumtoxina for headache prophylaxis in adult chronic migraine patients from two long-term, multicenter studies: compel vs. Preempt
    Aurora, S.
    Stark, R.
    Reppine, A.
    Adams, A. Manack
    Blumenfeld, A.
    CEPHALALGIA, 2015, 35 : 47 - 47
  • [39] Descriptive Comparison of the Efficacy and Safety of OnabotulinumtoxinA for Headache Prophylaxis in Adult Chronic Migraine Patients from Two Long-term, Multicenter Studies: COMPEL vs. PREEMPT
    Aurora, S.
    Stark, R.
    Reppine, A.
    Adams, Manack A.
    Blumenfeld, A.
    HEADACHE, 2015, 55 : 142 - 142
  • [40] Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study
    Navarro-Perez, Maria Pilar
    Gonzalez-Quintanilla, Vicente
    Munoz-Vendrell, Albert
    Madrigal, Elisabet
    Alpuente, Alicia
    Latorre, German
    Molina, Francis
    Monzon, Maria Jose
    Medrano, Vicente
    Garcia-Azorin, David
    Gonzalez-Oria, Carmen
    Gago-Veiga, Ana
    Velasco, Fernando
    Beltran, Isabel
    Morollon, Noemi
    Viguera, Javier
    Casas-Limon, Javier
    Rodriguez-Vico, Jaime
    Cuadrado, Elisa
    Irimia, Pablo
    Iglesias, Fernando
    Guerrero-Peral, angel Luis
    Belvis, Robert
    Pozo-Rosich, Patricia
    Pascual, Julio
    Santos-Lasaosa, Sonia
    FRONTIERS IN NEUROLOGY, 2024, 15
12345